EUVIMEDEUVIMED entdecken
Crossref

Spatial proteomics of tertiary lymphoid structures reveals correlation with immunotherapy response in Merkel cell carcinoma

Motoki Nakamura iD, Dai Ogata iD, Junji Kato, Yi-Wen Ko, Jiayue Hu, Maki Yoshimitsu, Tetsuya Magara, Shinji Kano, Reiko Nakamura, Hiroshi Kato, Takeo Maekawa, Masahito Yasuda und 5 weitere

British Journal of Dermatology · 17.04.2026 · 194 (5) · 888-898

DOI: 10.1093/bjd/ljaf525 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Dermatology, online erschienen am 29.12.2025. Verfasst von Motoki Nakamura und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Geriatric and Environmental Dermatology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan. Hauptthemen laut MEDLINE: Carcinoma, Merkel Cell, Tertiary Lymphoid Structures, Skin Neoplasms, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: Ministry of Education, Culture, Sports, Science, and Technology, Japan, Grant-in-Aid for Scientific Research, Grant-in-Aid for Early-Career Scientists.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Tertiary lymphoid structures (TLS) are ectopic lymphoid formations within or around tumours. They are emerging as important predictors of prognosis and response to immune checkpoint inhibitors (ICIs) in various cancers. However, in Merkel cell carcinoma (MCC), the correlation between TLS and ICI response has not yet been evaluated. Furthermore, the criteria for assessing TLS maturity vary by report, and there is no unified consensus.

Objectives

To investigate the relationship between TLS and ICI responsiveness in MCC using spatial proteomics at the single-cell level. By comparing the spatial characteristics of TLS in people whose disease responds to ICI and those whose disease does not, we also aimed to identify features related to functionality of TLS, distinct from the previously reported maturity of TLS.

Methods

We analysed 24 TLS from 13 patients with MCC treated with the anti-programmed cell death ligand 1 antibody avelumab, using the PhenoCyclerTM platform with 16 oligonucleotide-labelled antibodies. Infiltrating immune cells and tumour cells were phenotyped based on machine learning, and spatial single-cell analysis was performed, including cellular neighbourhood analysis and cell–cell correlation analysis.

Results

Our findings revealed that the number of TLS positively correlated with survival and ICI response (P = 0.03). The number of TLS observed in tumours was significantly higher in those whose disease responded to the ICI compared with those whose disease did not (P = 0.004). Cellular neighbourhood analysis and cell–cell correlation analysis demonstrated that in functional TLS in those whose disease responded to treatment, T cells infiltrated densely within B-cell clusters, extending close to follicular dendritic cells, and that CD4+ T cells adjacent to CD8+ T cells express programmed cell death protein 1 (PD-1). In contrast, in TLS in those whose disease did not respond to treatment, although the B-cell density was high, T cells did not infiltrate B-cell cluster areas but instead resided in the peripheral areas. Furthermore, it was found that CD8+ T cells and CD4+ T cells approaching B cells expressed PD-1.

Conclusions

We found a significant positive correlation between the number of TLS and ICI response in MCC. Additionally, our results suggest that the immune composition and spatial configuration within TLS may be important determinants of ICI efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Merkel CellTertiary Lymphoid StructuresSkin NeoplasmsImmune Checkpoint InhibitorsHumansMaleFemaleAgedProteomicsAged, 80 and overLymphocytes, Tumor-InfiltratingAntibodies, Monoclonal, HumanizedMiddle AgedSingle-Cell AnalysisTreatment OutcomeB7-H1 AntigenTumor Microenvironment

Substanzen

Immune Checkpoint InhibitorsavelumabAntibodies, Monoclonal, HumanizedB7-H1 Antigen

Autor:innen und Institutionen

  • Department of Geriatric and Environmental Dermatology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
  • Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan.
  • Department of Dermatology, Sapporo Medical University School of Medicine, Sapporo, Japan.
  • Department of Dermatology, Jichi Medical University Saitama Medical Center, Shimotsuke, Japan.
  • Department of Dermatology, Gunma University Graduate School of Medicine, Maebashi, Japan.
  • Department of Dermatology, Shinshu University, Matsumoto, Japan.

ORCID-Profile: Motoki Nakamura, Dai Ogata

Förderung

  • Ministry of Education, Culture, Sports, Science, and Technology, Japan
  • Grant-in-Aid for Scientific Research
  • Grant-in-Aid for Early-Career Scientists
  • Nagoya City University

Zitieren

APA

Nakamura, M., Ogata, D., Kato, J., Ko, Y. W., Hu, J., Yoshimitsu, M., Magara, T., Kano, S., Nakamura, R., Kato, H., Maekawa, T., Yasuda, M., Kiniwa, Y., Ishikawa, H., Nakamura, Y., Nagase, K., & Morita, A. (2026). Spatial proteomics of tertiary lymphoid structures reveals correlation with immunotherapy response in Merkel cell carcinoma. British Journal of Dermatology, 194(5), 888-898. https://doi.org/10.1093/bjd/ljaf525

Vancouver

Nakamura M, Ogata D, Kato J, Ko YW, Hu J, Yoshimitsu M, et al. Spatial proteomics of tertiary lymphoid structures reveals correlation with immunotherapy response in Merkel cell carcinoma. British Journal of Dermatology. 2026;194(5):888-898. doi:10.1093/bjd/ljaf525

BibTeX
@article{Nakamura2026,
  author = {Nakamura, Motoki and Ogata, Dai and Kato, Junji and Ko, Yi-Wen and Hu, Jiayue and Yoshimitsu, Maki and Magara, Tetsuya and Kano, Shinji and Nakamura, Reiko and Kato, Hiroshi and Maekawa, Takeo and Yasuda, Masahito and Kiniwa, Yukiko and Ishikawa, Hideyuki and Nakamura, Yasuhiro and Nagase, Kotaro and Morita, Akimichi},
  title = {Spatial proteomics of tertiary lymphoid structures reveals correlation with immunotherapy response in Merkel cell carcinoma},
  journal = {British Journal of Dermatology},
  year = {2026},
  volume = {194},
  number = {5},
  pages = {888--898},
  doi = {10.1093/bjd/ljaf525}
}
Kostenlos starten →